Clinical trials: Peripheral T Cell Lymphoma
Adult T-cell Leukemia-Lymphoma, Peripheral T-cell Lymphoma
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
To determine the maximum tolerated dose of lenalidomide in patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) who have previously received therapy for ATL and PTCL
- Trial name
- NCT01169298
- Testing
- Lenalidomide
- Where
- 6 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Celgene
Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL.
- Trial name
- NCT04745234
- Testing
- Mogamulizumab
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 34 people
- Sponsor
- Kyowa Kirin, Inc.
Lymphoma, T-Cell, Cutaneous
Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
In an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported…
- Trial name
- NCT00419367
- Testing
- Comparator: vorinostat
- Sponsor
- Merck Sharp & Dohme LLC
T-Cell Lymphoma
A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin
The main aim of this study is to describe how effective and safe the re-treatment of adults with cutaneous T-cell lymphoma (CTCL) with brentuximab vedotin is.
- Trial name
- NCT05886478
- Testing
- No intervention
- Where
- 11 sites in France, Germany and 2 more
- Volunteers
- 26 people
- Sponsor
- Takeda
Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.
- Trial name
- NCT07730515
- Testing
- XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended)
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Evopoint Biosciences Inc.
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
- Trial name
- NCT02567656
- Testing
- RP6530
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Rhizen Pharmaceuticals SA
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT01767766
- Testing
- TGR-1202
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- TG Therapeutics, Inc.
Extranodal NK/T-cell Lymphoma, Nasal Type
Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal…
- Trial name
- NCT04509466
- Testing
- Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
- Where
- China
- Volunteers
- 41 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Graft Versus Host Disease, Leukemia
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
RATIONALE: OTI-010 may be effective for graft-versus-host disease prophylaxis (prevention) in patients who are undergoing donor peripheral stem cell transplantation for hematologic malignancies (cancer of the blood or bone…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00081055
- Testing
- autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
Peripheral T-cell Lymphoma
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT04569032
- Testing
- brentuximab vedotin, cyclophosphamide, doxorubicin
- Where
- 63 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Lymphoma
Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer…
- Trial name
- NCT00030589
- Testing
- bexarotene, methoxsalen, UV light therapy
- Where
- 19 sites in United States
- Sponsor
- Millennix
Extranodal NK/T-cell Lymphoma
VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients
The study aims to evaluate the efficacy and safety of VT-EBV-N (EBV-CTL) administration in ENKL patients after complete remission (CR).
- Trial name
- NCT03671850
- Testing
- VT-EBV-N
- Where
- 8 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- ViGenCell Inc.
Mycosis Fungoides
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
In this pilot study, pembrolizumab will be administered via DoseConnect in patient with relapsed or refractory cutaneous T-cell lymphoma to assess through pharmacodynamic assessment in the tumor tissue to assess if lymphatic…
- Trial name
- NCT04118868
- Testing
- Pembrolizumab administered using the Sofusa® DoseConnect™
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sorrento Therapeutics, Inc.
Lymphoma, B-Cell, T-Cell Lymphoma
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with hematologic malignancies.
- Trial name
- PI3K (NCT02017613)
- Testing
- RP6530
- Where
- 3 sites in France, Italy
- Volunteers
- 35 people
- Sponsor
- Rhizen Pharmaceuticals SA
Peripheral T-cell Lymphoma
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
- Trial name
- NCT01689220
- Testing
- SP-02L (darinaparsin for injection)
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Solasia Pharma K.K.
Relapsed or Refractory Peripheral T-Cell Lymphoma
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T cell lymphoma.
- Trial name
- NCT04108325
- Testing
- YY-20394
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas.
- Conditions
- Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- PXD101-CLN-6 (NCT00274651)
- Testing
- belinostat
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 53 people
- Sponsor
- Valerio Therapeutics
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.
- Trial name
- NCT06122389
- Testing
- SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cutaneous T-Cell Lymphoma
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
- Trial name
- NCT00744991
- Testing
- Enzastaurin
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell…
- Trial name
- NCT05934513
- Testing
- GFH009
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.